Tuberculosis: current challenges and beyond

Author:

Villar-Hernández Raquel,Ghodousi ArashORCID,Konstantynovska Olha,Duarte RaquelORCID,Lange ChristophORCID,Raviglione MarioORCID

Abstract

Despite being a preventable and curable disease, tuberculosis (TB) is still a major global health threat and the second leading cause of death due to an infectious agent worldwide. All the efforts invested to end TB have resulted overall in rather slow decreases in TB incidence and mortality rates, which have been further negatively affected by the ongoing coronavirus disease 2019 (COVID-19) pandemic. While the majority of targets of the End TB Strategy remain off track, and we have not yet overcome the disruptions caused by the COVID-19 pandemic, recent conflicts such as the ongoing war in Ukraine are threatening the decrease of the burden of TB even further. To get back on track and get closer to ending TB, we need urgent, global, well-structured and committed multi-sectoral actions that go beyond national and global TB programmes with the support of deep investments in research and facilitation of equitable and rapid implementation of innovation worldwide.

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference18 articles.

1. World Health Organization (WHO) . Global Tuberculosis Report 2022. Geneva, WHO, 2022. www.who.int/publications/i/item/9789240061729

2. World Health Organization (WHO) . Global Tuberculosis Report 2021. Geneva, WHO, 2021. www.who.int/publications/i/item/9789240037021

3. World Health Organization (WHO) . Global Tuberculosis Report 2020. Geneva, WHO, 2020. www.who.int/publications/i/item/9789240013131

4. World Health Organization (WHO) . Western Pacific Regional Framework to End TB: 2021–2030. Manila, WHO Regional Office for the Western Pacific, 2022. www.who.int/publications/i/item/9789290619703

5. Increase in tuberculosis diagnostic delay during first wave of the COVID-19 pandemic: data from an Italian infectious disease referral hospital;Di Gennaro;Antibiotics,2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3